BioCentury
ARTICLE | Company News

Symplmed, Xoma deal

July 15, 2013 7:00 AM UTC

Symplmed acquired from Xoma exclusive, U.S. rights to develop and commercialize a fixed-dose combination of perindopril/amlodipine and a sublicense to promote Aceon perindopril erbumine in the U.S. Xoma will receive an undisclosed equity stake in Symplmed and is eligible for up to double-digit royalties on sales of perindopril/amlodipine. Symplmed CEO Erik Emerson and CMO August Troendle, former Xoma employees, founded Symplmed in May to market the products. Symplmed is also developing its Dyrct Axess technology, which tracks treatment progress through a web-based feedback tool. ...